2010| 2009 |2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001

July 27 2010
-Suven spends 22% of revenue on R&D
 PAT up by 58% for the 1st Quarter

July 12 2010
-Suven Life Sciences presenting at International Conference on Alzheimer’s Disease (ICAD)

June 16 2010
-Suven Life Sciences secures Two (2) Product Patents from Japanese Patent Office (JPO) for their NCE’s to treat Central Nervous System (CNS) disorders

May 25 2010
-Suven’s partnering and fundraising activity at C21 BioVentures™

May 12 2010
-Suven Life Sciences secures 3rd Canadian and 6th Eurasian Patent for their NCE

May 3 2010
-Prof. Syed Hasnain joins Suven as Additional Director

Apr 30 2010
-Suven spends 26% of Revenue on R&D for the year ended March 2010

Apr 28 2010
-Suven Life Sciences secures Product Patents from India and New Zealand

Apr 22 2010
-Suven Life Sciences secures Three Australian Patents on NCEs

Apr 12 2010
-Suven Life Sciences secures First Product Patent from Japanese Patent Office (JPO) for their NCE to treat Central Nervous System (CNS) disorders

Mar 29 2010
-Suven Life Sciences secures 8th Product Patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders

Mar 22 2010
-Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System (CNS) disorders

Jan 27 2010
-Suven spends 34% of Revenue on R&D for the 3rd quarter ending Dec’ 09

Jan 12 2010
-Suven Secures Two product patents in China and Russia

Dec 14 2009
-Suven Secures two Product patents from Canadian Intellectual Property Office

Nov 30 2009
-Suven Life Sciences secures Three European Patents on NCEs

Oct 31 2009
-Suven spends 29.78% of Revenue on R&D for the quarter ending Sep 09

Oct 20 2009
-Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual Meeting, SFN-2009 at Chicago, USA

Oct 14 2009
-Suven’s Clinical Candidate SUVN-502 For Alzheimer’s disease Secures product patents in several Key markets in the world

Sep 14 2009
-Suven Life Sciences secures Two US Patents on NCEs

Sep 07 2009
-Suven achieves 1st Milestone payment in Drug Discovery collaboration

July 28 2009
-Suven’s profit up by 37%, Spends 22% of Revenue on R&D .

July 27 2009
-Suven Presented Positive Phase-I clinical data of SUVN-502 for Alzheimer’s disease at ICAD 2009, Vienna, Austria.

May 6 2009
-SUVEN’S UNIT- I RECEIVES US FDA ACCEPTANCE.

Apr 29 2009
-Suven’s revenue up by 19%, Spends 22% of Revenue on R&D.

Apr 9 2009
-Suven completes Phase I Clinical Trials Multiple Ascending Dose of SUVN-502 in Switzerland.

Jan 19 2009
-Suven’s revenue up by 21%, Spends 24% of Revenue on R&D.

Jan 13 2009
-Suven participation at Biotech Showcase 2009.

Nov 18 2008
-Suven participation at Bio-Europe 2008.

Nov 11 2008
-Suven Presentation at Rodman & Renshaw 10th Annual Healthcare Conference at New York being held from 10-12 November 2008

Oct 31 2008
Suven's net up by 50%, Spends 17% of Revenue on R&D

Oct 13 2008
-SUVN-502 data being presented at 16th BioPartnering in London

Sep 29 2008
-Suven completed Phase-I Clinical Trials Single Ascending Dose of SUVN-502 in Switzerland

Sep 25 2008
-DCGI nod to conduct Phase-I Clinical Trials of SUVN-502 for Alzheimer’s disease

 Nov 05 2007
-Suven Life Sciences presenting Pre-clinical data of their NCE's at Society for Neuroscience Annual Meeting, SFN-2007 at San Diego, USA

Oct  31 2007
-Suven Life Sciences secures Two (2) Product Patents in Australia & New Zealand for their New Chemical Entities (NCEs)

Oct  30 2007
-Suven's half yearly revenues increase by 10%, R&D spent at 26% of Revenue

Oct 25 2007
-Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection

Oct 23 2007
-Suven Life Sciences Secures Three (3) Indian Product Patents For Their New Chemical Entities (NCEs)

Jul 31 2007
-Suven PAT up by 51%;R&D spend at 33% of Revenue

Jul 12 2007
-Suven Life Sciences files its first Investigational New Drug (IND) application of its NCE SUVN-502 in India to conduct Phase 1 clinical trials

Jul 5 2007
-Suven Life Sciences presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507 at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience to be held at Melbourne, Australia

Jun 11 2007
-Suven's unit III receives US FDA acceptance

Apr 26 2007
-Suven yearly revenues increase by 38%, PAT up by 33% ; R&D spend at 24% of Revenue

Jan 29 2007
-Suven Income up by 35%, Spends 17% on R&D
-Suven shares split from Rs 2 per share to Re. 1 per share and issues bonus shares in the ratio of 1:1

-Suven renewed ISO 14001 certification

-Suven renewed ISO 9001 certification

-Suven received OHSAS 18001 certification

Oct 2004
-Suven pharma promoter invests $1-m in CRO, data development


Apr 2004
-Suven Life Sciences net Income up by 27.76%


Apr 27, 2004
-Suven Life income up 10 p.c.

Mar 23, 2004
-Suven to set up Rs 100 cr unit in Vizag

Feb 5, 2004
-Suven Life Sciences net up 57 percent

Feb 1, 2004
-Suven profit up 5% to Rs. 1.91 cr in Q3

Jan 1, 2004
-Suven gets ISO 14001 certification

Dec 18, 2003
-Suven Life to raise Rs 27.4 cr through preferential issue
-Borregaard exits Suven Life Sciences

Dec 5, 2003
-Suven board okays merger of subsidiary
-Suven Life board decides to split shares

Nov 28, 2003
-Suven board to consider merger of subsidiary
-Suven Life Sciences may merge arm with self
-Suven plans pref issue, share split, merger of arm

Nov 24, 2003
-Suven graduating itself to life sciences player

Oct 23, 2003
-The $15 billion bulk drug opportunity
-CPhI: Downpour of deals

Sep 29, 2003
-Venkat Jasti re-elected president of BDMA

Sep 6, 2003
-Spurious drugs eating into AP’s export share

Aug 07, 2003
-Suven Pharma rechristened Suven Life

Aug 02, 2003
-Suven Pharma is Suven Life now

August 01, 2003
-Suven Q1 net up 63% at Rs 2.3 cr

Jul 7, 2003
-PA fellowship Award

Jun12, 2003
-Venkat Jasti asks Govt. & Industry to play pro-active role to tap the potential post-2005

Jun 2, 2003
-Venkat Jasti joins Pharmabiz advisory board

May 20, 2003
-SUVEN Pharma acquires assets of New Jersey (USA) based SYNTHON CHIRAGENICS

Apr 26, 2003
-SUVEN spent 21 % of its revenue in R & D

Apr 21, 2003
-SUVEN eyes discovery research

Mar 25, 2003
-Drug discovery boutique set up
-3 Indian Pharma form alliance
-Desi Pharma trio ally for new patent regime
-Life sciences alliance formed — 3 pharma cos tie up with US firm
-3 cos. forge alliance with U.S. firm
-3 drug firms join hands

Dec 24, 2002
-SUVEN Pharma sees revenue jump after April 2004

Oct 18, 2002
-SUVEN starts research academy
-SUVEN Pharma to collaborate in promoting the Centre of Excellence in clinical research

Aug 07 , 2002
-SUVEN sets the stage for Contract Research in India

Jun 03 , 2002
-Speeding up drug discovery

Dec 25, 2001
-Pharma sector hopes to have Export Promotion Council soon
-Andhra Pradesh to set up Pharma City

Dec 24, 2001
-After IT and BT, Pharma catches Chandrababu Naidu's eye
-Forget IT, Pharma is the new mantra
-Pharmaexcil
-Seperate Export Promotion Council for pharma sector on anvil
-Pharmaexcil likely to be operational 

Dec 23, 2001
-Pharma City in Vizag

Dec 21, 2001
-Vizag's Pharma City to get a booster dose
-Vizag Pharma City Phase-I to be operational by 2003

Nov 23, 2001
-A.P. to attract global majors as healthcare capital

Nov 1, 2001
-SUVEN Pharma